Skip to main content
28°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aptose Bioscns
(NQ:
APTO
)
0.1925
+0.0086 (+4.68%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aptose Bioscns
< Previous
1
2
Next >
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
December 12, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
December 09, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
December 03, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
November 25, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
November 22, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
November 20, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Third Quarter 2024
November 08, 2024
Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Results from Special Meeting of Shareholders
September 05, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
August 30, 2024
Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Adjournment of its Special Meeting of Shareholders
August 15, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Second Quarter 2024
August 08, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Receipt of Deficiency Notice from Nasdaq
July 19, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Results from Annual and Special Meeting of Shareholders
June 18, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
June 14, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 03, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 31, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the First Quarter 2024
May 14, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
May 06, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Fourth Quarter and Full Year 2023
March 26, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
March 18, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
January 31, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
January 26, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
December 09, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
November 30, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Third Quarter 2023
November 09, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
November 02, 2023
Data from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML Patients
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
October 30, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
October 26, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
October 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
October 16, 2023
Company to Hold Clinical Update Webcast; Details Forthcoming
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.